- Viropil is a fixed dose combination W.H.O. recommended first-line antiretrovirals (ARV) complete regimen treatment option for people living with HIV/AIDS. The recommendation is based on Dolutegravir’s improved tolerability, higher antiretroviral efficacy, lower rates of treatment discontinuation, a higher genetic barrier to resistance and fewer drug interactions than other ARV drugs. Additionally, both the U.S. Department of Health and Human Services and the European AIDS Clinical Society include Dolutegravir as a preferred medicine on their HIV/AIDS treatment guidelines.
Please refer to the manufacturer’s website for all this medicine’s information